QUOTED. July 17, 2018. David Brunel.
Biodesix Inc. is acquiring Integrated Diagnostics Inc. for both its flagship XL2 lung-cancer test and to upgrade its ability to develop new pharma companion diagnostics. See what Biodesix CEO David Brunel said about it here.
"That is perfect for us, because our primary call point is the pulmonologist and this is one of the big questions they're asking us to help address. It was just a natural fit for our [customer] call-point and with our strategy of trying to be a comprehensive provider of all the necessary tools to help physicians diagnose and treat this disease." –David Brunel, CEO, Biodesix Inc.
Click here for a free trial of Medtech Insight